
Claims

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:



R^1 is selected from hydrogen, halogen, hydroxy, cyano, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{1-4} haloalkyl, an optionally substituted C_{1-4} alkoxy and an optionally substituted C_{1-4} haloalkoxy;

R^2 is a substituted 6-15 membered heteroaryl or a substituted 6-15 membered heterocyclyl, wherein the heteroaryl and the heterocyclyl independently contains 1-4 heteroatoms selected from N, O and S, and the heteroaryl and the heterocyclyl is substituted with an optionally substituted bicyclo[1.1.1]pentyl; and wherein the heteroaryl and the heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of halogen, cyano, an unsubstituted C_{1-4} alkyl, an unsubstituted C_{1-4} haloalkyl, an unsubstituted C_{1-4} alkoxy, an alkyl mono-substituted amine and an alkyl di-substituted amine;

R^3 is selected from hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl, wherein when substituted, R^3 is substituted by one or more substituents selected from halogen, cyano, an unsubstituted C_{1-4} alkyl, an optionally substituted aryl, $-C(O)R^{5A}$, $-SO_2R^{5B}$, $-NHC(O)R^{5C}$ and $-(CR^{6A}R^{6B})_nNR^{7A}R^{7B}$;

X^1 is O, S or NR^4;

R^4 is selected from hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{1-4} haloalkyl and an optionally substituted C_{3-8} cycloalkyl;

R^{5A}, R^{5B} and R^{5C} are independently selected from hydrogen, an optionally substituted C_{1-4} alkyl, an optionally substituted C_{1-4} haloalkyl, an optionally substituted C_{3-8} cycloalkyl, an

optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

R^{6A} and R^{6B} are independently selected from hydrogen, halogen, an optionally substituted C_1-$_4$ alkyl, an optionally substituted C_1-$_4$ haloalkyl and an optionally substituted C_3-$_8$ cycloalkyl;



R^{7A} and R^{7B} are independently selected from hydrogen, an optionally substituted C_1-$_4$ alkyl, an optionally substituted C_1-$_4$ haloalkyl and an optionally substituted C_3-$_8$ cycloalkyl;







A^1 is CR^8;

R^8 is selected from hydrogen, halogen, cyano, an optionally substituted C_1-$_4$ alkyl, an optionally substituted C_1-$_4$ haloalkyl and an optionally substituted C_{3-8} cycloalkyl;




m is 0 or 1; and

n is 0, 1, 2 or 3.

2. The compound of Claim 1, wherein R^2 is selected from a substituted indolyl, a substituted indazolyl, a substituted 4,5,6,7-tetrahydroindazolyl, a substituted  and n substituted .

3. The compound of Claim 1, wherein R^2 is ,  or ; R^{2A}, R^{2B} and R^{2C} are each an optionally substituted bicyclo[1.1.1]pentyl; and wherein each of ,  and  are optionally further

substituted by one or more substituents selected from the group consisting of halogen, cyano, an unsubstituted C_1-$_4$ alkyl, an unsubstituted C_1-$_4$ haloalkyl, an unsubstituted C_1-$_4$ alkoxy, an alkyl mono-substituted amine and an alkyl di-substituted amine.

4. The compound of Claim 3, wherein R^2 is ,  or ; and R^{2A}, R^{2B} and R^{2C} are each an optionally substituted bicyclo[1.1.1]pentyl.

5. The compound of any one of Claims 2-4, wherein the optionally substituted bicyclo[1.1.1]pentyl substituted on R^2 is a fluoro-substituted bicyclo[1.1.1]pentyl, a chloro-substituted bicyclo[1.1.1]pentyl or a cyano-substituted bicyclo[1.1.1]pentyl.

6. The compound of any one of Claims 2-4, wherein the optionally substituted bicyclo[1.1.1]pentyl substituted on R^2 is an unsubstituted bicyclo[1.1.1]pentyl.

7. The compound of any one of Claims 1-6, wherein m is 0.

8. The compound of any one of Claims 1-6, wherein m is 1.

9. The compound of Claim 8, wherein X^1 is NR^4.

10. The compound of Claim 9, wherein R^4 is hydrogen.

11. The compound of Claim 9, wherein R^4 is an optionally substituted C_1-$_4$ alkyl.

12. The compound of Claim 11, wherein R^4 is an unsubstituted C_1-$_4$ alkyl.

13. The compound of any one of Claims 1-12, wherein R^3 is an optionally substituted C_1-$_4$ alkyl.

14. The compound of Claim 13, wherein R^3 is a substituted C_1-$_4$ alkyl.

15. The compound of any one of Claims 1-12, wherein R^3 is an optionally substituted heterocyclyl.

16. The compound of Claim 15, wherein the optionally substituted heterocyclyl is an optionally substituted monocyclic heterocyclyl.

17. The compound of Claim 14, wherein R^3 is substituted by $-(CR^{6A}R^{6B})_nNR^{7A}R^{7B}$.

18. The compound of Claim 17, wherein n is 0.

19. The compound of Claim 17, wherein n is 1.

20. The compound of Claim 17 or 19, wherein R^{6A} and R^{6B} are each hydrogen.

21. The compound of any one of Claims 17-20, wherein R^{7A} and R^{7B} are each an optionally substituted C_{1-4} alkyl.







22. The compound of Claim 21, wherein R^{7A} and R^{7B} are each an unsubstituted C_{1-4} alkyl.











23. The compound of any one of Claims 1-22, wherein R^{1} is an optionally substituted C_{1-4} alkoxy.


24. The compound of Claim 23, wherein R^{1} is an unsubstituted C_{1-4} alkoxy.


25. The compound of any one of Claims 1-24, wherein R^{8} is hydrogen.


26. A compound selected from:



,

,

,

,

,

,



,

,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.


27. A compound having the structure:  , or a pharmaceutically acceptable salt thereof.

28. A compound having the structure:  , or a pharmaceutically acceptable salt thereof.

29. A compound having the structure:  , or a pharmaceutically acceptable salt thereof.

30. A compound having the structure:  , or a pharmaceutically acceptable salt thereof.

31. A compound having the structure: , or a pharmaceutically acceptable salt thereof.

32. A compound having the structure: , or a pharmaceutically acceptable salt thereof.

33. A pharmaceutical composition comprising an effective amount of the compound of any one of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

34. Use of an effective amount of a compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating or treating a cancer, wherein the cancer is selected from a lung cancer, a pancreatic cancer, a colon cancer, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer and a kidney carcinoma.

35. Use of an effective amount of a compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer selected from a lung cancer, a pancreatic cancer, a colon cancer, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer and a kidney carcinoma.

36. Use of an effective amount of a compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating or

treating a malignant growth or tumor, wherein the malignant growth or tumor is due to a cancer selected from a lung cancer, a pancreatic cancer, a colon cancer, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer and a kidney carcinoma.

37. Use of an effective amount of a compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer by inhibiting the activity of EGFR, wherein the EGFR has one or more selected from a deletion in exon 19, an insertion in exon 20, a mutation at L858R and an acquired EGFR T790M mutation; and wherein the inhibiting the activity of EGFR inhibits a cancer cell selected from a lung cancer cell, a pancreatic cancer cell, a colon cancer cell, a breast cancer cell, a prostate cancer cell, a head and neck cancer cell, an ovarian cancer cell, a brain cancer cell and a kidney carcinoma cell.